Fulgent Genetics Inc Market Cap ($562.69 Million)
Market Cap & Net Worth: Fulgent Genetics Inc (FLGT)
Fulgent Genetics Inc market cap. Fulgent Genetics Inc (NASDAQ:FLGT) has a market capitalization of $562.69 Million ($562.69 Million) as of October 31, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11356 globally and #2958 in its home market, demonstrating a 7.70% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Fulgent Genetics Inc's stock price $21.68 by its total outstanding shares 27515293 (27.52 Million).
Fulgent Genetics Inc Market Cap History (2016–2026)
Fulgent Genetics Inc market cap history from 2016 to 2026. Data shows growth from $318.35 Million to $596.53 Million (8.89% CAGR). Check FLGT share price today for real-time trading data and today's change.
Index Memberships
Fulgent Genetics Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.02% | #320 of 976 |
|
NASDAQ Composite
IXIC
|
$40.85 Trillion | 0.00% | #1168 of 3165 |
Weight: Fulgent Genetics Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Fulgent Genetics Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Fulgent Genetics Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Also see FLGT cash flow conversion for how efficiently the company converts equity into cash flow.
Latest Price to Sales (P/S) Ratio
2.24x
Fulgent Genetics Inc's market cap is 2.24 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $318.35 Million | $18.28 Million | -$5.39 Million | 17.42x | N/A |
| 2017 | $120.52 Million | $18.73 Million | -$2.66 Million | 6.43x | N/A |
| 2018 | $87.22 Million | $21.36 Million | -$4.49 Million | 4.08x | N/A |
| 2019 | $354.95 Million | $32.53 Million | $366.00K | 10.91x | 969.80x |
| 2020 | $1.43 Billion | $421.71 Million | $214.31 Million | 3.40x | 6.69x |
| 2021 | $2.77 Billion | $992.58 Million | $104.34 Million | 2.79x | 26.53x |
| 2022 | $819.41 Million | $618.97 Million | $143.40 Million | 1.32x | 5.71x |
| 2023 | $795.47 Million | $289.21 Million | -$167.82 Million | 2.75x | N/A |
| 2024 | $508.21 Million | $283.47 Million | -$42.71 Million | 1.79x | N/A |
| 2025 | $722.83 Million | $322.67 Million | -$60.51 Million | 2.24x | N/A |
Competitor Companies of FLGT by Market Capitalization
Companies near Fulgent Genetics Inc in the global market cap rankings as of October 31, 2026. See Fulgent Genetics Inc net asset quality index to understand what proportion of total assets are financed by equity.
Key companies related to Fulgent Genetics Inc by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #87 globally with a market cap of $224.59 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #136 globally with a market cap of $167.39 Billion USD.
- Natera Inc (NASDAQ:NTRA): Ranked #480 globally with a market cap of $56.33 Billion USD.
- WuXi AppTec Co Ltd (SHG:603259): Ranked #525 globally with a market cap of $51.71 Billion USD ( CN¥353.41 Billion CNY).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #87 | Thermo Fisher Scientific Inc | NYSE:TMO | $224.59 Billion | $709.18 |
| #136 | Danaher Corporation | NYSE:DHR | $167.39 Billion | $236.98 |
| #480 | Natera Inc | NASDAQ:NTRA | $56.33 Billion | $436.00 |
| #525 | WuXi AppTec Co Ltd | SHG:603259 | $51.71 Billion | CN¥142.89 |
Market Capitalization of Fulgent Genetics Inc (2016–2026)
Market capitalization of Fulgent Genetics Inc from 2016 to today. Between 2016 and today, Fulgent Genetics Inc's market cap moved from $318.35 Million to $ 596.53 Million, with a yearly change of 8.89%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $596.53 Million | -17.47% |
| 2025 | $722.83 Million | +42.23% |
| 2024 | $508.21 Million | -36.11% |
| 2023 | $795.47 Million | -2.92% |
| 2022 | $819.41 Million | -70.39% |
| 2021 | $2.77 Billion | +93.07% |
| 2020 | $1.43 Billion | +303.88% |
| 2019 | $354.95 Million | +306.94% |
| 2018 | $87.22 Million | -27.63% |
| 2017 | $120.52 Million | -62.14% |
| 2016 | $318.35 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 30th, 2026 the market cap of Fulgent Genetics Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $562.69 Million USD |
| MoneyControl | $562.69 Million USD |
| MarketWatch | $562.69 Million USD |
| marketcap.company | $562.69 Million USD |
| Reuters | $562.69 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Fulgent Genetics Inc
Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company's clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pa… Read more